Intest Res.  2019 Jan;17(1):63-69. 10.5217/ir.2018.00077.

Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients

• Imbrizi MR
• Magro DO
• Secundo TD
• Cunha-Silva M
• Kotze PG
• Montes CG
• Almeida JR
• Cabral VL

• KMID: 2438444
• DOI: http://doi.org/10.5217/ir.2018.00077

Abstract

BACKGROUND/AIMS
Inflammatory bowel disease (IBD) are chronic entities characterized by local and systemic inflammation and may be associated with thrombosis. The aim of this study was to identify the prevalence of thromboembolic events (TEE) in hospitalized IBD patients and identify risk factors for their occurrence.
METHODS
This retrospective, single-center study included patients treated at a Brazilian IBD referral unit between 2004 and 2014. Patients hospitalized for more than 48 hours due to active IBD and who did not receive prophylaxis for TEE during hospitalization were included. Patients were allocated to 2 groups: those with TEE up to 30 days or at the time of hospitalization (TEE-group) and patients without TEE (control-group). Clinical and laboratory characteristics were evaluated.
RESULTS
Of 53 patients evaluated, 69,8% with Crohn's disease (CD) and 30.2% with ulcerative colitis (UC). The prevalence of TEE 30 days before or during hospitalization was 15.1%, with 10.8% in CD and 25% in UC. In the TEE group, mean serum albumin was 2.06 g/dL versus 3.30 g/dL in the control group. Patients with albumin levels below 2.95 g/dL (43.18%) had a higher risk of developing TEE (relative risk, 1.72; 95% confidence interval, 1.17-2.53) (P < 0.001).
CONCLUSIONS
Albumin levels were significantly lower in patients with TEE, and hypoalbuminemia was considered a risk factor for the development of TEE in this population.

Keyword

Crohn disease; Colitis, ulcerative; Thromboembolism; Thromboembolic prophylaxis; Serum albumin

MeSH Terms

Colitis, Ulcerative
Crohn Disease
Hospitalization
Humans
Hypoalbuminemia*
Inflammation
Inflammatory Bowel Diseases*
Inpatients*
Prevalence
Referral and Consultation
Retrospective Studies
Risk Factors*
Serum Albumin
Thromboembolism
Thrombosis
Serum Albumin

Figure

• 

  Fig. 1. Patients flowchart. TEE, thromboembolic events.

• 

  Fig. 2. Receiver operating characteristic (ROC) analysis. Area under the ROC curve of 0.859 (P=0.002; 95% CI, 0.75–0.97; sensitivity 100%; specificity 72.2% [=1–0.278]).

Reference

1. Giannotta M, Tapete G, Emmi G, Silvestri E, Milla M. Thrombosis in inflammatory bowel diseases: what’s the link? Thromb J. 2015; 13:14.

2. Bargen JA, Barker NW. Extensive arterial and venous thrombosis complicating chronic ulcerative colitis. Arch Intern Med. 1936; 58:17–31.

3. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut. 2004; 53:542–548.

4. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005; 3:617–628.

5. Papa A, Gerardi V, Marzo M, Felice C, Rapaccini GL, Gasbarrini A. Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment. World J Gastroenterol. 2014; 20:3173–3179.

6. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 Suppl A:5A–36A.

7. Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology. 2014; 146:835–848.

8. Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet. 1980; 1:514.

9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2:1041–1048.

10. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995; 854:1–452.

11. Nguyen GC, Sharma S. Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm Bowel Dis. 2013; 19:2182–2189.

12. Olson NC, Cushman M, Lutsey PL, et al. Inflammation markers and incident venous thromboembolism: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost. 2014; 12:1993–2001.

13. Paar M, Rossmann C, Nusshold C, et al. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One. 2017; 12:e0182997.

14. Jørgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb Res. 1980; 17:13–18.

15. Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost. 2010; 104:100–104.

16. Winstedt D, Hanna J, Schött U. Albumin-induced coagulopathy is less severe and more effectively reversed with fibrinogen concentrate than is synthetic colloid-induced coagulopathy. Scand J Clin Lab Invest. 2013; 73:161–169.

17. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):381S–453S.